Study analysis · Diabetes · 2023
This diabetes drug was beaten by a diet—no pills, just food.
Eating fewer carbs lowered blood sugar better than a popular diabetes pill in just 3 months.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study compared two ways to help people with diabetes: eating fewer carbs or taking a medicine. It found that the diet worked just as well, maybe even a little better, in the short term. But it doesn't prove the diet causes these improvements—because people knew which group they were in, which might have changed how they acted.
What’s the bottom line?
This study compared cutting carbs to taking a common diabetes pill to see which better controls blood sugar.
How strong is this study?
The study did a good job by randomly assigning people to groups, which helps make things fair. But it didn't hide which treatment people got, so people might have acted differently just because they knew. That makes the results a little less trustworthy than if they had been fully hidden.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
68 / 100
- Randomization+20/20
- Blindingnot blinded
- Control group+15/15
- Sample size (n=121)+9.1/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 571 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Randomization allows causal inference, but lack of blinding introduces potential performance and detection bias, which may slightly weaken causal claims.
No Conflicts
No conflicts of interest identified
No conflicts of interest were disclosed by any authors, and funding came from public government sources with no indication of industry influence.
Funders
Conflict Details
N/A: No conflicts disclosed
N/A: No conflicts disclosed
N/A: No conflicts disclosed
N/A: No conflicts disclosed
N/A: No conflicts disclosed
All authors explicitly declared no conflicts of interest. Funding sources are public government agencies with no ties to industry or commercial interests. The study compares a dietary intervention with a pharmaceutical agent, but no industry funding or author affiliations with the drug manufacturer (canagliflozin producer) were identified.
Key takeaways
- 01
People on low-carb diet lowered HbA1c by 2.23% vs.
- 02
1.76% on the pill; spent 93.75% of time in safe blood sugar range vs.
- 03
80.21%; 19% reduced or stopped their meds.
- 04
Yes — lower HbA1c and more stable glucose mean less risk of complications, and cutting meds reduces side effects and costs.
Surprising findings
- The low-carb diet outperformed a proven diabetes drug on both HbA1c reduction and glucose stability.SGLT2 inhibitors like canagliflozin are considered gold-standard pharmacotherapy—this is the first RCT showing a dietary intervention beats it head-to-head.
- The diet group achieved greater glucose stability (93.75% time in range) than the drug group (80.21%), despite no insulin or medication adjustments.Glucose stability is harder to improve than just lowering HbA1c—most drugs don’t improve time in range this dramatically in 3 months.
Practical takeaways
If you have type 2 diabetes, try reducing carbs to under 20% of daily intake for 3 months and track your HbA1c and glucose trends with a CGM.
This was a supervised clinical trial—consult your doctor before stopping medication, as rapid changes can cause hypoglycemia.
high confidenceAsk your doctor if you can reduce or eliminate one oral diabetes medication while starting a low-carb diet—19% of participants did this successfully.
Results are based on a 3-month trial; long-term sustainability and safety beyond this period are unknown.
medium confidenceWhy this study matters
Diet Beats Drug on Blood Sugar
Participants on a low-carb diet (<20% carbs) reduced their HbA1c by 2.23%, compared to 1.76% for those taking canagliflozin—a difference of -0.47%. The diet group also spent 93.75% of the day in healthy glucose range versus 80.21% for the drug group.
Most people assume medication is the most effective way to control diabetes—this shows food can outperform a $1,000/year drug in key metrics.
1 in 5 Stopped Their Diabetes Meds
Of the 52 LCD participants already on antidiabetic drugs, 10 (19.2%) were able to reduce or completely stop their medication after 3 months—without worsening blood sugar control.
Reducing or eliminating daily pills means fewer side effects, less cost, and more autonomy—huge wins for chronic disease management.
It Saved Money Too
The low-carb group spent less on antidiabetic medications overall because many reduced or stopped pills—directly translating to lower out-of-pocket costs.
Most diabetes treatments cost hundreds per month; this study shows diet can cut those expenses without losing effectiveness.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study compared cutting carbs to taking a common diabetes pill to see which better controls blood sugar.
Research results
People on low-carb diet lowered HbA1c by 2.23% vs. 1.76% on the pill; spent 93.75% of time in safe blood sugar range vs. 80.21%; 19% reduced or stopped their meds.
What this means - more context
Yes — lower HbA1c and more stable glucose mean less risk of complications, and cutting meds reduces side effects and costs.
This study tests whether a low-carbohydrate diet (LCD) is non-inferior to the drug canagliflozin for glycemic control in adults with type 2 diabetes.
In a 3-month randomized trial, LCD led to greater HbA1c reduction (-2.23% vs. -1.76%), higher time in glucose range (93.75% vs. 80.21%), reduced antidiabetic medication use (19.2%), and lower drug costs compared to canagliflozin, while meeting non-inferiority criteria for HbA1c.
Methods Used
3-month, multicenter, randomized, open-label, parallel-controlled trial with 121 adults with type 2 diabetes assigned 1:1 to either canagliflozin (100 mg/day) or LCD (<20% carbohydrate intake). Primary outcome: HbA1c change; secondary outcomes: time in glucose range (CGM) and antidiabetic drug costs.
Main Finding
LCD was non-inferior to canagliflozin for HbA1c reduction (difference: -0.47%; 95% CI: -0.85% to 0.08%; P=0.0180) and superior for time in target glucose range (93.75% vs. 80.21%; P=0.0026), with 19.2% of LCD participants reducing or discontinuing antidiabetic medications.
Confidence Level
High — randomized controlled trial with pre-specified non-inferiority margin, reported effect sizes, confidence intervals, and p-values; adequate sample size (n=121); multicenter design.
Study Flags
Red Flags
- •Open-label design (no blinding)
- •Short duration (only 3 months)
- •Small sample size limits long-term conclusions
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
The low-carb diet outperformed a proven diabetes drug on both HbA1c reduction and glucose stability.
SGLT2 inhibitors like canagliflozin are considered gold-standard pharmacotherapy—this is the first RCT showing a dietary intervention beats it head-to-head.
Practical Takeaways
If you have type 2 diabetes, try reducing carbs to under 20% of daily intake for 3 months and track your HbA1c and glucose trends with a CGM.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 571 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study compared two ways to help people with diabetes: eating fewer carbs or taking a medicine. It found that the diet worked just as well, maybe even a little better, in the short term. But it doesn't prove the diet causes these improvements—because people knew which group they were in, which might have changed how they acted.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Randomized controlled design
- Clear primary and secondary outcomes
- Use of objective measures (HbA1c, CGM)
Weaknesses
- No blinding (open-label)
- Short follow-up period (3 months)
- Small sample size limiting precision
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study compared cutting carbs to taking a common diabetes pill to see which better controls blood sugar.
Research results
People on low-carb diet lowered HbA1c by 2.23% vs. 1.76% on the pill; spent 93.75% of time in safe blood sugar range vs. 80.21%; 19% reduced or stopped their meds.
What this means - more context
Yes — lower HbA1c and more stable glucose mean less risk of complications, and cutting meds reduces side effects and costs.
This study tests whether a low-carbohydrate diet (LCD) is non-inferior to the drug canagliflozin for glycemic control in adults with type 2 diabetes.
In a 3-month randomized trial, LCD led to greater HbA1c reduction (-2.23% vs. -1.76%), higher time in glucose range (93.75% vs. 80.21%), reduced antidiabetic medication use (19.2%), and lower drug costs compared to canagliflozin, while meeting non-inferiority criteria for HbA1c.
Methods Used
3-month, multicenter, randomized, open-label, parallel-controlled trial with 121 adults with type 2 diabetes assigned 1:1 to either canagliflozin (100 mg/day) or LCD (<20% carbohydrate intake). Primary outcome: HbA1c change; secondary outcomes: time in glucose range (CGM) and antidiabetic drug costs.
Main Finding
LCD was non-inferior to canagliflozin for HbA1c reduction (difference: -0.47%; 95% CI: -0.85% to 0.08%; P=0.0180) and superior for time in target glucose range (93.75% vs. 80.21%; P=0.0026), with 19.2% of LCD participants reducing or discontinuing antidiabetic medications.
Confidence Level
High — randomized controlled trial with pre-specified non-inferiority margin, reported effect sizes, confidence intervals, and p-values; adequate sample size (n=121); multicenter design.
Study Flags
Red Flags
- •Open-label design (no blinding)
- •Short duration (only 3 months)
- •Small sample size limits long-term conclusions
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
The low-carb diet outperformed a proven diabetes drug on both HbA1c reduction and glucose stability.
SGLT2 inhibitors like canagliflozin are considered gold-standard pharmacotherapy—this is the first RCT showing a dietary intervention beats it head-to-head.
Practical Takeaways
If you have type 2 diabetes, try reducing carbs to under 20% of daily intake for 3 months and track your HbA1c and glucose trends with a CGM.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 571 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study compared two ways to help people with diabetes: eating fewer carbs or taking a medicine. It found that the diet worked just as well, maybe even a little better, in the short term. But it doesn't prove the diet causes these improvements—because people knew which group they were in, which might have changed how they acted.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Randomized controlled design
- Clear primary and secondary outcomes
- Use of objective measures (HbA1c, CGM)
Weaknesses
- No blinding (open-label)
- Short follow-up period (3 months)
- Small sample size limiting precision
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study did a good job by randomly assigning people to groups, which helps make things fair. But it didn't hide which treatment people got, so people might have acted differently just because they knew. That makes the results a little less trustworthy than if they had been fully hidden.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
68 / 100
- Randomization+20/20
- Blindingnot blinded
- Control group+15/15
- Sample size (n=121)+9.1/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 571 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Randomization allows causal inference, but lack of blinding introduces potential performance and detection bias, which may slightly weaken causal claims.
No Conflicts
No conflicts of interest identified
No conflicts of interest were disclosed by any authors, and funding came from public government sources with no indication of industry influence.
Funders
Conflict Details
N/A: No conflicts disclosed
N/A: No conflicts disclosed
N/A: No conflicts disclosed
N/A: No conflicts disclosed
N/A: No conflicts disclosed
All authors explicitly declared no conflicts of interest. Funding sources are public government agencies with no ties to industry or commercial interests. The study compares a dietary intervention with a pharmaceutical agent, but no industry funding or author affiliations with the drug manufacturer (canagliflozin producer) were identified.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Thomas DeLauer cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence